Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,099 public trials 2,041 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Autologous Transplant in HIV Patients (BMT CTN 0803)

NCT01141712

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +17 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Diego Medical Center La Jolla, California, United States
  • UCLA Los Angeles, California, United States
  • University of CA, SF San Francisco, California, United States
View all 16 locations
View Trial Details
Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

NCT02955823

Conditions
Diffuse Large B-cells Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia Meldola, Forlì-Cesena, Italy
  • A.O. C. Panico - U.O.C Ematologia e Trapianto Tricase, Lecce, Italy
  • Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS - Ematologia Reggio Emilia, Italy
  • Ospedale Dell'Angelo - U.O. Ematologia Mestre, Venezia, Italy
View all 18 locations
View Trial Details
Completed

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

NCT03873493

Conditions
Cancer, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Dana-Farber Cancer Institute /ID# 207728 Boston, Massachusetts, United States
  • Mayo Clinic - Rochester /ID# 207692 Rochester, Minnesota, United States
  • University of Texas MD Anderson Cancer Center /ID# 207746 Houston, Texas, United States
  • Peter MacCallum Cancer Ctr /ID# 209554 Melbourne, Victoria, Australia
View all 15 locations
View Trial Details
Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

NCT02141282

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 128535 La Jolla, California, United States
  • University of California, Los Angeles /ID# 127262 Los Angeles, California, United States
  • Stanford University School of Med /ID# 126495 Stanford, California, United States
  • Georgetown University Hospital /ID# 127261 Washington D.C., District of Columbia, United States
View all 15 locations
View Trial Details

Related conditions